<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antimicrobial treatment of tunneled hemodialysis catheter-related bloodstream infection&lt;sup&gt;[1-4]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antimicrobial treatment of tunneled hemodialysis catheter-related bloodstream infection<sup>[1-4]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Antimicrobial treatment of tunneled hemodialysis catheter-related bloodstream infection<sup>[1-4]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="25%"></colgroup><colgroup width="50%"></colgroup> <tbody> <tr> <td class="subtitle1">Treatment</td> <td class="subtitle1">Dose and schedule for adult patients*</td> <td class="subtitle1">Administration</td> </tr> <tr class="divider_bottom"> <td>Vancomycin<sup>¶</sup></td> <td> <p>High flux: 20 mg/kg IV loading dose, then 1 g IV in last hour of each HD session</p> Low flux: 500 mg in last hour of each HD session</td> <td> <ul> <li>Use actual (ie, estimated dry) body weight to determine loading dose</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Ceftazidime</td> <td>1 g IV post-HD</td> <td> <ul> <li>Some centers administer a 2 g dose when the next HD session is 72 hours later</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Cefepime</td> <td>1.5 to 2 g IV post-HD</td> <td> <ul> <li>Alternative if ceftazidime is unavailable</li> <li>Risk of neurotoxicity in drug accumulation</li> <li>2 g dose for pathogen MIC ≥4 mcg/mL or when next HD session is 72 hours later<sup>[1,2]</sup></li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Cefazolin</td> <td>2 g IV post-HD</td> <td> <ul> <li>For pathogen-directed therapy of MSSA</li> <li>Some centers administer a 3 g dose when the next HD session is 72 hours later</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Gentamicin or tobramycin</td> <td>1 to 2 mg/kg IV in last hour of each HD session (not to exceed 100 mg per dose)<sup>Δ</sup></td> <td> <ul> <li>Alternative in settings with elevated rates of resistance to ceftazidime or severe hypersensitivity to third generation cephalosporins<sup>◊</sup></li> <li>Ototoxicity in up to 20% when used &gt;48 to 72 hours, particularly in combination with vancomycin</li> <li>Weight scalar to determine dose: <ul> <li>Underweight: Use actual (dry) body weight</li> <li>Normal weight or overweight: Use IBW</li> <li>Obese (ie, &gt;1.25 IBW): Use ABW</li> </ul> </li> <li>A calculator for estimating IBW and ABW is available separately in UpToDate</li> </ul> </td> </tr> <tr> <td>Daptomycin</td> <td> <p>High flux: 9 mg/kg IV in last hour of each HD session</p> Low flux: 7 mg/kg in last hour of each HD session</td> <td> <ul> <li>For pathogen-directed therapy or history of vancomycin-resistant <em>Enterococcus</em> and an alternative in patients with documented vancomycin hypersensitivity (excluding vancomycin flushing syndrome)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Above dosing recommendations are based upon thrice weekly HD sessions. For empiric therapy, an appropriate combination of the above agents is necessary. For approach to antimicrobial selection and tailoring, as well as issues surrounding removal of the dialysis catheter and use of adjunctive antibiotic locks, refer to the UpToDate review of tunneled hemodialysis catheter-related bacteremia.</div><div class="graphic_footnotes">IV: intravenous; HD: hemodialysis; MIC: minimum inhibitory concentration; MSSA: methicillin-sensitive <em>Staphylococcus aureus</em>; IBW: ideal body weight; ABW: adjusted body weight.<br/>* General recommendation on dose schedule shown. Schedule may require adjustment based upon clinical setting; ie, doses may be administered either in the last hour of dialysis session or after dialysis depending upon practical considerations.<br/>¶ This dosing may be used when serum vancomycin concentrations are unavailable. Dose recommendations based upon serum concentration monitoring are provided in a separate UpToDate topic review and table of vancomycin parenteral dosing and monitoring.<br/>Δ In patients who require an aminoglycoside for &gt;48 to 72 hours, UpToDate contributors obtain predialysis serum concentrations to guide adjustment of the postdialysis dose until a stable dose regimen is established. Recommendations for dose adjustment based upon serum concentrations are provided in a separate UpToDate topic review of dosing and administration of parenteral aminoglycosides.<br/><span class="lozenge">◊</span> Patients with a history of mild to moderate allergy (eg, mild rash) or intolerance to penicillins or first generation cephalosporins can usually tolerate ceftazidime. Refer to separate UpToDate topic review of cephalosporin hypersensitivity and cross-reactivity.</div><div class="graphic_reference">References: 
<ol>
<li>Descombes E, Martins F, Hemett OM, et al. Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study. BMC Pharmacol Toxicol 2016; 17:4.</li>
<li>Allon M. Treatment guidelines for dialysis catheter-related bacteremia: an update. Am J Kidney Dis 2009; 54:13.</li>
<li>Schmaldienst S, Traunmüller F, Burgmann H, et al. Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes. Eur J Clin Pharmacol 2000; 56:61.</li>
<li>Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All rights reserved.</li></ol></div><div id="graphicVersion">Graphic 126615 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
